article thumbnail

STAT+: Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more

STAT

… Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S. Noom offers its compounded semaglutide at a starting price of $149 for the first month. The current legislative authority for the programs expires at the end of September 2027.

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid. One expires next year and the other in 2027, well beyond the original patent expiration date. Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. The research projected a compound annual growth rate (CAGR) of 16.8 billion by 2027 appeared first on European Pharmaceutical Review. percent from $7.7

article thumbnail

Pharmaceutical sterility testing market to grow from $2.07b in 2027

European Pharmaceutical Review

billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29

article thumbnail

Rising Demand for Customized Medication To Transform Compounding Pharmacies Market Outlook

Pharma Mirror

Compounding pharmacies, which involve the preparation and selling of prescribed medicines are gaining massive popularity across the healthcare sector owing to the rising awareness regarding the benefits of compounded medications.

article thumbnail

Lonza to enhance commercial antibody-drug conjugate supply capacity

European Pharmaceutical Review

The new filling line is projected to be operational in 2027. The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Approximately 115 new jobs are expected to be created.

article thumbnail

Piramal Pharma Solutions announces $80M expansion at Lexington Facility

Express Pharma

The site specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products. Upon completion of the expansion, scheduled for Q1 2027, this will increase to over 240 annual batches. Current capacity at the Lexington site stands at 104 product batches per year.